BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dieterich DT, Bernstein D, Flamm S, Pockros PJ, Reau N. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States. Aliment Pharmacol Ther 2020;52:1311-22. [PMID: 32813292 DOI: 10.1111/apt.16044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tomić Mahečić T, Baronica R, Mrzljak A, Boban A, Hanžek I, Karmelić D, Babić A, Mihaljević S, Meier J. Individualized Management of Coagulopathy in Patients with End-Stage Liver Disease. Diagnostics (Basel) 2022;12. [PMID: 36553179 DOI: 10.3390/diagnostics12123172] [Reference Citation Analysis]
2 Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271 [DOI: 10.4240/wjgs.v14.i11.1260] [Reference Citation Analysis]
3 Ding Z, Wu H, Zeng Y, Kuang M, Yang W, Meng Z, Chen Y, Hao C, Zou S, Sun H, Liu C, Lin K, Shi G, Wang X, Fu X, Chen R, Chen Y, Liang R, Kano T, Pan H, Yang S, Fan J, Zhou J. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures. Hepatol Int 2023;17:180-9. [PMID: 36258065 DOI: 10.1007/s12072-022-10421-9] [Reference Citation Analysis]
4 Wang K, Shao Y, Li C, Bao J, Zhu W, Zhou Y. Effect of thrombopoietin receptor agonist on health-related quality of life and platelet transfusion burden for patients with myelodysplastic syndromes: a systematic review and meta-analysis. Ann Hematol 2022. [PMID: 35976414 DOI: 10.1007/s00277-022-04950-4] [Reference Citation Analysis]
5 Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol 2022; 28(30): 4061-4074 [DOI: 10.3748/wjg.v28.i30.4061] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gigante E, Sutter O, Nahon P, Seror O, Nault J. Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. Liver Cancer International 2022;3:37-46. [DOI: 10.1002/lci2.35] [Reference Citation Analysis]
7 Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 2021;51:1181-95. [PMID: 34555262 DOI: 10.1111/hepr.13715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz Ž, Štabuc B, Trifan A. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures. J Clin Med 2021;10:5419. [PMID: 34830701 DOI: 10.3390/jcm10225419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]